淋巴结边缘区淋巴瘤24例临床分析

发布时间：2018-02-26 18:12

本文关键词： 结边缘区淋巴瘤利妥昔单抗临床分析　出处：《中国医学科学院学报》2017年02期 　论文类型：期刊论文

【摘要】：目的总结淋巴结边缘区淋巴瘤(NMZL)的临床特点。方法回顾性分析本院2002年1月至2013年9月淋巴瘤中心住院诊治的NMZL患者,总结临床和实验室检查特点,并对治疗疗效、预后进行统计分析。结果 24例经病理证实的NMZL患者,中位年龄54.4(28~70)岁,男女比例1∶1。95%患者存在骨髓受累,乳酸脱氢酶增高40.9%(9/22),丙肝抗体阳性8.3%(2/24),自身抗体阳性33.3%(6/18),单克隆球蛋白阳性率33.3%(8/24)。所有患者CD19、CD20阳性,CD10阴性;CD5阳性率10%(1/10),CD23阳性率50%(5/10),但无CD5/CD23同时阳性患者。治疗总缓解率81.25%,完全缓解率56.2%;应用利妥昔单抗联合化疗较单纯化疗总缓解率及完全缓解率有提高趋势,但差异无统计学意义(P=0.136,P=0.262)。结论结边缘区淋巴瘤发病率低,男女发病率相当,容易骨髓侵犯;利妥昔单抗较单纯化疗组有可能提高疗效(总缓解率及完全缓解率),甚至有可能改善无进展生存。
[Abstract]:Objective to summarize the clinical features of lymph node marginal zone lymphoma (NMZL). Methods the clinical and laboratory features of NMZL patients hospitalized in our hospital from January 2002 to September 2013 were analyzed retrospectively. Results the median age of 24 patients with pathologically proved NMZL was 54.4- 2870 years old. The ratio of male and female was 1: 1.95% with bone marrow involvement. Lactate dehydrogenase was increased by 40.9% of 22%, hepatitis C antibody by 8.32%, autoantibody by 33.3% or 6 / 18, monoclonal globulin by 33.3% and by 8 / 24%. The positive rate of CD19 + CD20 + CD10 + CD10 negative CD10 + CD5 was 50% / 10% in all patients, but there was no CD5/CD23 positive at the same time. The total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%. The overall remission rate and complete remission rate of Rituximab combined chemotherapy were higher than those of chemotherapy alone. But the difference was not statistically significant. Conclusion the incidence of lymphomas in the marginal zone is low, the incidence of male and female is similar, and the incidence of bone marrow invasion is easy. Rituximab may improve the curative effect (total remission rate, complete remission rate, or even progressive survival rate) compared with chemotherapy alone group.
【作者单位】：中国医学科学院北京协和医学院血液病医院血液学研究所淋巴瘤中心;
【分类号】：R733.1

【相似文献】